Coconut Oil

Small molecule

UUniversity of Louisville

Coconut Oil is one of 45 small molecule programs targeting Interstitial Cystitis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial CystitisActive, not recruiting

Interstitial CystitisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Interstitial Cystitis

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 2

Elmiron

WWim Janssens

Approved

1 3

Xolair

Roche

Phase 3

1 4

Myrbetriq

Astellas

Phase 3

1 5

Cimzia

UCB

Phase 3

1 6

Intron a

Sanofi

Phase 3

1 7

Humira

CCelltrion

Phase 3

1 8

Sodium Hyaluronate

Sanofi

Phase 3

1 9

Quietus

Merck & Co.

Phase 2

1 10

Ajovy

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interstitial Cystitis1 trial

Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome

Recruiting·UUniversity of Louisville·Phase 1/2·NCT04845217·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Coconut Oil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Coconut Oil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Coconut Oil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Louisville company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity of Louisville

Coconut Oil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Interstitial Cystitis1 trial

References

Drug Info

Quick Facts

Related News